Competition & Markets Authority
Illumina’s takeover of PacBio raises competition concerns
The proposed merger of 2 DNA sequencing system firms, Illumina and PacBio, raises competition concerns, an in-depth CMA review has provisionally found.
The Competition and Markets Authority (CMA) has issued its provisional findings as part of a Phase 2 merger investigation of the proposed $1.2 billion takeover by Illumina, Inc. (Illumina) of Pacific Biosciences of California, Inc (PacBio).
The companies are both global suppliers of Next-Generation DNA sequencing systems to organisations across the world, including UK universities, laboratories and research institutes. DNA sequencing systems are vital to the study of genetic variation in humans and other species, for purposes such as essential disease research and drug development.
The CMA’s provisional conclusion is that the merger will result in a significant loss of competition between the 2 companies, with few alternative providers of DNA sequencing systems remaining.
DNA sequencing is a highly concentrated industry and Illumina holds an approximately 80% share of the market globally and 90% in the UK. The CMA’s investigation has found that PacBio is one of Illumina’s closest competitors and vice versa. The companies’ internal documents often refer to each other as competitive threats and this is consistent with the views of customers and the remaining competitors.
PacBio also recently released new, innovative technology and is well-positioned to be a stronger competitor in the future. The CMA is therefore concerned that the deal would remove a significant competitive threat to Illumina.
DNA sequencing is a dynamic and rapidly developing sector where innovation is key. The CMA considers that competition is one of the main factors that drives innovation and is concerned that the loss of PacBio as an independent competitor will lead to a reduction in overall levels of innovation in the market.
Stuart McIntosh, the Inquiry Chair, yesterday said:
DNA sequencing is a highly concentrated industry and given the strength of Illumina in this market, and the limited number of alternative providers, the removal of an innovative competitor like PacBio is likely to have a significant impact on competition.
This could harm critically important innovation in the systems created to support DNA sequencing and lead to less choice, higher prices or lower quality as a result of the merger.
For more information, visit the case page.
Notes to Editors:
- Next-Generation Sequencing underlies the study of all organisms, and informs knowledge spanning basic biology to complex human diseases such as cancer. Next-Generation Sequencing is a dynamic industry, with new sequencing platforms and updates to technology being released frequently.
- All the CMA’s functions in phase 2 merger inquiries are performed by inquiry groups chosen from the CMA’s panel members. The appointed inquiry group are the decision-makers on phase 2 inquiries.
- The CMA’s panel members come from a variety of backgrounds, including economics, law, accountancy and/or business; the membership of an inquiry group usually reflects a mix of expertise and experience.
- The members of this inquiry group are Stuart McIntosh (Chair), Humphrey Battcock, Colleen Keck and John Thanassoulis.
Press office 020 3738 6460
Out-of-hours mobile (for urgent media requests only) 07774 134814
During working hours, please contact the main press office number. For any urgent out of hours media questions, contact the out of hours mobile.
Latest News from
Competition & Markets Authority
Facebook and eBay pledge to combat trading in fake reviews09/01/2020 09:20:00
Following action from the CMA, Facebook and eBay have committed to combatting the trade of fake and misleading reviews on their sites.
Illumina/PacBio abandon merger03/01/2020 10:20:00
Illumina has abandoned its anticipated $1.2 billion takeover of PacBio after an in-depth CMA merger probe highlighted serious competition concerns.
LN-Gaiety’s purchase of MCD cleared by CMA20/12/2019 12:20:00
An in-depth CMA investigation has found that Live Nation-Gaiety’s proposed purchase of MCD does not raise competition concerns.
CMA lifts the lid on digital giants18/12/2019 13:20:00
The CMA has published an update in its examination of online platforms and digital advertising, uncovering new detail about how the sector’s biggest names operate.
Estate agents fined over half a million pounds for price fixing18/12/2019 09:10:00
3 Berkshire estate agents have been fined more than £600,000 for illegally fixing the minimum commission rates they charged their customers.
Pharmaceutical merger cleared by CMA16/12/2019 11:25:00
The CMA has cleared the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical company Roche Holdings.
Amazon’s Deliveroo investment raises competition concerns12/12/2019 11:20:00
Amazon’s investment in Deliveroo raises serious competition concerns for UK customers that may require an in-depth investigation by the CMA.
CMA Statement on design, construction and fit-out services director disqualification11/12/2019 12:20:00
Individual directors should be held accountable if their company breaks competition law.